We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Stock Moves -0.17%: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $59.95, moving -0.17% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.81%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq lost 1.27%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.09% over the past month. This has lagged the Medical sector's loss of 1.62% and the S&P 500's gain of 5.06% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. On that day, BMY is projected to report earnings of $1.49 per share, which would represent year-over-year growth of 27.35%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.37 billion, up 72.68% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.24 per share and revenue of $41.88 billion. These results would represent year-over-year changes of +33.05% and +60.19%, respectively.
Investors might also notice recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.85% higher. BMY is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, BMY currently has a Forward P/E ratio of 9.63. For comparison, its industry has an average Forward P/E of 22.63, which means BMY is trading at a discount to the group.
Investors should also note that BMY has a PEG ratio of 1.12 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.74 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 184, which puts it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Stock Moves -0.17%: What You Should Know
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $59.95, moving -0.17% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.81%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq lost 1.27%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.09% over the past month. This has lagged the Medical sector's loss of 1.62% and the S&P 500's gain of 5.06% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. On that day, BMY is projected to report earnings of $1.49 per share, which would represent year-over-year growth of 27.35%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.37 billion, up 72.68% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.24 per share and revenue of $41.88 billion. These results would represent year-over-year changes of +33.05% and +60.19%, respectively.
Investors might also notice recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.85% higher. BMY is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, BMY currently has a Forward P/E ratio of 9.63. For comparison, its industry has an average Forward P/E of 22.63, which means BMY is trading at a discount to the group.
Investors should also note that BMY has a PEG ratio of 1.12 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.74 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 184, which puts it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.